The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer | Zendy

John M. Kaczmar | Zendy; Ranee Mehra | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer

Author(s) -

John M. Kaczmar,

Ranee Mehra

Publication year - 2015

Publication title -

therapeutic advances in respiratory disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.022

H-Index - 37

eISSN - 1753-4666

pISSN - 1753-4658

DOI - 10.1177/1753465815597834

Subject(s) - ceritinib , medicine , lung cancer , crizotinib , alectinib , oncology , anaplastic lymphoma kinase , intensive care medicine , malignant pleural effusion

Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase ( ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research